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Abstract  
Background: The implantable cardioverter defibrillators (ICDs) are increasingly being used as a 
treatment  modality  for  life  threatening  tachyarrhythmia.  The  purpose  of  this  study  was  to 
compare  the  frequency  of  complications  and  mortality  between  single-chamber  and  dual-
chamber ICD implantation in Shahid Rajaie cardiovascular center.
Methods and results: Between January 2000 and December 2004, 234 patients received ICD by 
a percutaneous transvenous approach and were followed for 33 ± 23 months. The cumulative 
incidence  of  complications  was  9.4%  over  the  follow-up  period.  There  was  no  significant 
difference in overall complication rate between single chamber (VR) and dual chamber (DR) 
ICD groups in  the  follow-up period  (P= 0.11).  The risk  of  complications  did  not  have  any 
statistically significant difference in secondary versus primary prevention groups (P=0.06). The 
complications  were  not  associated  with  the  severity  of  left  ventricular  systolic  dysfunction 
(P=0.16).The  frequency  of  lead-related  complications  was  higher  in  dual  chamber  ICDs  in 
comparison with single chamber ICDs (P=0.02). There was no significant difference in mortality 
between different sex groups (P=0.37), different indications for ICD implantation (P=0.43) or 
between VR and DR ICD groups (P= 0.55). Predictors of mortality were NYHA class III or more 
(P<0.001), age >65 years (P=0.011) and LVEF<30% (P<0.001). The mortality in patients with 
CAD  and  DCM  were  significantly  higher  than  those  with  other  structural  heart  diseases 
(P=0.001).
Conclusions: Close monitoring of patients during the first 2 month after ICD implantation is 
recommended  because  the  majority  of  complications  occur  early  after  the  procedure.
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Introduction
            The  implantable  cardioverter  defibrillators  (ICDs)  are  increasingly  being  used  as  a 
treatment   modality   for   high   risk  s urvivors   of   life-threatening  tachyarrhythmia.1,2  Major 
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technological advances like the introduction of transvenous defibrillation leads and "active can" 
concept  have  simplified  the  implantation  of  ICDs  and  have  reduced  implantation-related 
complications  but  still  there  are  considerable  rate  of  complications  in  most  of  the 
electrophysiologic centers.3,4
            The purpose of the current  study was to identify  and characterize prospectively the 
frequency of lead and implant-related complications and also mortality in patients with single-
chamber versus dual-chamber ICD implantation.
Methods
Patients:  
            Between January, 2000 and December, 2004, 234 patients received ICDs in our center. 
All of them included in the study and were followed for 33 ±23 months. The primary end point 
of  the  study  was  actuarial  survival.  The  secondary  end  point  was  nonfatal  complications, 
including inappropriate ICD therapy, lead-related and implant-related complications. The study 
was approved by local Ethics Committee and written informed consent was obtained from all the 
patients.
Implanted ICDs and programming:
            ICD system manufacturers  included Medtronic  and  St  Jude  systems in  160 and 75 
patients respectively. Atrial leads included 1688 T or 1642T for St Jude and 5076 for Medtronic 
systems. Ventricular leads included 1570,1572,1571,1580 and 1581 for St Jude and 6944, 6947 
and 6948 for Medtronic systems. All of the ventricular leads were bipolar. In implanted devices 
all the detection and discrimination criteria were activated with the nominal values. In all the 
devices we defined ventricular fibrillation zone (300ms) plus one VT zone (400 ms).  If  the 
patient had an episode of spontaneous or induced sustained monomorphic VT slower than 370 
ms we extended the VT zone to VT cycle length plus 40ms. In the VT detection zone the first 
therapy was three antitachycardia burst pacing. We used the nominal values of the ICDs for the 
duration and tachyarrhythmia detection criteria. Antibradycardia pacing was programmed in VVI 
mode with pacing rate of 40 beats per minute in all VR and DR ICDs, unless the patients needed 
dual  chamber  pacing,  those  with  long  QT  syndrome  and  hypertrophic  obstructive 
cardiomyopathy.
Implantation techniques:
            The  implantation  routes  were  either  subclavian  or  Axillary  veins  percutaneously  in 
electrophysiology laboratory by an electrophysiologist.
Follow-up protocol:
            The patients were followed after 1 month postoperatively and every 3 months thereafter 
and upon receiving high voltage therapy in our outpatient ICD clinic. ICD evaluations during 
follow-up visits included routine clinically appropriate measurements including interrogation of 
the device for tachyarrhythmia episodes, evaluation of sensing and pacing thresholds and lead 
impedance. Floppy diskettes were used to retrieve all episodes of ICD therapy. All the episodes 
resulted  in  ICD  therapy,  studied  independently  by  two  electrophysiologists  to  define  the 
diagnosis.  All  the  episodes  were  categorized  as  appropriate  or  inappropriate.  ICD-related 
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complications were documented, as were mortality and cause of death. Chest radiography (CXR) 
was  obtained  before  hospital  discharge  and  every  6  months  to  confirm  radiographic  lead 
integrity.  Clinical  evaluation  of  patients  included  history  and  physical  examination  of  the 
implantation site. Complications were defined as unexpected adverse events that were felt to be 
related to the implant procedure or to the ICD lead and generator system.
Statistical analysis:
            Baseline  characteristics  and  complications  were  summarized  as  the  mean ±  SD for 
continuous variables and otherwise as percentage. SPSS 13 software (SPSS Inc., Chicago, IL, 
USA) was used for data storage and analysis. Qualitative characteristics were compared using the 
Pearson’s chi square and Fischer exact tests. Kaplan-Meyer survival curves were calculated. Log 
rank statistics  were used to  compare the distribution of  time to  complications  and mortality 
between different  ICD groups.  Two-tailed  P <  0.05  were  considered  significant.  Regression 
analysis  was  performed  to  evaluate  the  effect  of  variables  on  mortality  and  complications.
Results
Baseline characteristics:
            Baseline characteristics of the patients are summarized in Table 1. Table 2 compares the 
baseline characteristics of the patients in VR and DR ICD groups.
Table1: Baseline characteristics of patients
CAD= Coronary artery disease, DCM= Dilated cardiomyopathy,
HCM= Hypertrophic cardiomyopathy, NYHA= New York Heart Association
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Table2: Comparison of baseline characteristics between single and dual chamber devices.
ICD-VR= Single chamber implantable cardioverter-defibrillator, ICD-DR=Dual 
chamber implantable  cardioverter-defibrillator,  LVEDd= Left  ventricular  end 
diastolic diameter, LVESd= Left ventricular end systolic diameter, LVEF= Left 
ventricular  ejection  fraction,  NYHA=  New  York  Heart  Association,  CAD= 
Coronary artery disease, DCM= Dilated cardiomyopathy, HCM= Hypertrophic 
cardiomyopathy.
Mortality:
            Three patients (1.2%) died during the first  month after ICD implantation because of 
multi-organ  failure,  massive  pulmonary  emboli  and  acute  coronary  syndrome.  The  1-year 
survival rate was 94.9% and 94.1% for VR and DR ICDs respectively. The overall survival rate 
during  follow-up  was  90.6%  and  88.9%  for  VR and  DR ICDs  respectively.  There  was  no 
significant difference in mortality between different sex groups (P=0.37), different indications 
for  ICD implantation  (P=0.43)  or  between  VR and  DR ICD groups  (P=  0.55)  (Figure 1). 
Univariate  regression  analysis  showed  predictors  of  mortality  as  NYHA  class  III  or  more 
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